Pilot Study to Assess the Proteome in Human Atrial Tissue
Pilot Study to Assess the Proteome in Human Atrial Tissue
The concept of diabetic cardiomyopathy was initially defined more than 30 years ago, as
 cardiac failure in diabetic subjects in the absence of underlying coronary artery disease.
 Diabetes is also thought to contribute to earlier stage cardiac systolic dysfunction and/or
 to isolated diastolic dysfunction, in excess of underlying coronary artery disease and
 hypertension. More globally, it is recognized that subjects with type 2 diabetes have more
 extensive cardiovascular disease and a worse outcome for a similar level of disease than
 non-diabetic subjects. Despite this epidemiological evidence, the biological programming
 underpinning the myriad presentations of the diabetic heart' are poorly characterized in
 humans.

 Proteomics has emerged as an unbiased technology that enables the measurement of large
 numbers of steady-state protein levels. The potential to identify a diabetes associated
 proteomic signature in the heart would be a novel approach to identify putative biological
 programs altered by the diabetic state.

 A portion of the right atrial appendage is removed to insert the cardiac bypass machine
 cannula in certain cardiothoracic procedures. This tissue is usually discarded, however, we
 propose that it could be employed to examine whether otherwise similar subjects with and
 without diabetes have distinct atrial proteomic signatures. This pilot study may provide
 insight into potential biological pathways that orchestrate the worse cardiac prognosis in
 type 2 diabetic versus non diabetic control subjects.
The concept of diabetic cardiomyopathy was initially defined more than 30 years ago, as
 cardiac failure in diabetic subjects in the absence of underlying coronary artery disease.
 Diabetes is also thought to contribute to earlier stage cardiac systolic dysfunction and/or
 to isolated diastolic dysfunction, in excess of underlying coronary artery disease and
 hypertension. More globally, it is recognized that subjects with type 2 diabetes have more
 extensive cardiovascular disease and a worse outcome for a similar level of disease than
 non-diabetic subjects. Despite this epidemiological evidence, the biological programming
 underpinning the myriad presentations of the diabetic heart' are poorly characterized in
 humans.

 Proteomics has emerged as an unbiased technology that enables the measurement of large
 numbers of steady-state protein levels. The potential to identify a diabetes associated
 proteomic signature in the heart would be a novel approach to identify putative biological
 programs altered by the diabetic state.

 A portion of the right atrial appendage is removed to insert the cardiac bypass machine
 cannula in certain cardiothoracic procedures. This tissue is usually discarded, however, we
 propose that it could be employed to examine whether otherwise similar subjects with and
 without diabetes have distinct atrial proteomic signatures. This pilot study may provide
 insight into potential biological pathways that orchestrate the worse cardiac prognosis in
 type 2 diabetic versus non diabetic control subjects.
-  INCLUSION CRITERIA:

 Subjects must be 18-80 years of age.

 Subjects must provide informed, written consent to donate tissue that would otherwise be
 discarded post-cardiac surgery.

 Subjects undergoing elective coronary artery bypass surgery and or aortic valve replacement
 surgery.

 EXCLUSION CRITERIA:

 Subjects in atrial fibrillation or having a history of atrial fibrillation in the 2 weeks
 period prior to surgery.

 Use of intravenous anti-arrhythmic therapy.

 Subjects unable to give informed consent.

 Subjects with a fasting glucose of greater than 110 mg/dl that have not been defined as
 diabetic.